Gemtuzumab ozogamicin (MYLOTARG) expanded access protocol for treatment of patients in the United States with relapsed/ refractory acute myelogenous leukemia who may benefit from treatment and have no access to other comparable/alternative therapy
This protocol will allow single agent use of Mylotarg at <_9 mg/m2/dose for AML [or in combination with all-trans retinoic acid (ATRA) and/or arsenic trioxide for treatment of APL] and will also allow use of Mylotarg at doses up to 3 mg/m2/dose in combination with anthracycline or nucleoside-antagonist containing treatment regimens. This is an open-label (USA only) expanded access protocol to treat approximately100 patients with relapsed or refractory AML. This protocol will allow the investigator to choose for each patient enrolled an optimal treatment plan, choosing from several Mylotarg-containing treatment regimens.
Study Number: 

PH 275915

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail